v3.3.1.900
Selected Quarterly Financial Data (Unaudited) (Details Textual) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Jan. 03, 2016
Sep. 27, 2015
Jun. 28, 2015
Mar. 29, 2015
Dec. 28, 2014
Sep. 28, 2014
Jun. 29, 2014
Mar. 30, 2014
Jan. 03, 2016
Dec. 28, 2014
Dec. 29, 2013
Restructuring Cost and Reserve [Line Items]                      
Restructuring charges                 $ 509 $ 0 $ 0
Selected Quarterly Financial Data Unaudited (Textual) [Abstract]                      
Integration costs after tax $ 59       $ 237 $ 130 $ 104 $ 84      
Business Combination, Integration Related Costs 83       325 167 144 118      
Litigation income expense net after-tax   $ (348) $ (23) $ 253 (652) (231) (342)        
Litigation Settlement, Expense   $ 409 $ 134   692 285 $ 276   141 1,253 2,276
Cost associated with the DePuy ASR Hip recall program, after tax       122   111          
Litigation And Recall Expense       139   126          
Gain on sale of assets after tax           1,100          
Gain (Loss) on Sale of Assets and Asset Impairment Charges           1,900     2,583 2,383 113
Other Tax Benefit               $ (398)      
research and development after tax 156       115            
Other Selling and Marketing Expense           $ 220          
In-process research and development 214       $ 156       224 178 580
Asset Impairment Charges                 624 410 739
After Tax Restructuring Charge 415                    
Medical Devices [Member]                      
Restructuring Cost and Reserve [Line Items]                      
Restructuring charges $ 590               590    
Gain (Loss) Related to Litigation Settlement       $ 402         600    
Selected Quarterly Financial Data Unaudited (Textual) [Abstract]                      
Business Combination, Integration Related Costs                 196 754 683
Litigation Settlement, Expense                 5 907 1,975
Litigation And Recall Expense                 148 126 251
Gain (Loss) on Sale of Assets and Asset Impairment Charges                 1,300 1,899  
In-process research and development                 10 $ 31 $ 66
Asset Impairment Charges                 $ 346